Department of Medicine and Regulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Diabetes Metab J. 2012 Aug;36(4):255-61. doi: 10.4093/dmj.2012.36.4.255. Epub 2012 Aug 20.
Oxidative stress has been paid increasing attention to as an important causative factor for diabetic vascular complications. Among possible various sources, accumulating evidence has indicated that NAD(P)H oxidase may be the most important source for reactive oxygen species production in diabetic vascular tissues. The mechanisms underlying activation and up-regulation of NAD(P)H oxidase has been supposed to be mediated by high glucose-induced protein kinase C (PKC) activation. In this review article, activation of local renin-angiotensin II system induced by chymase activation is also shown to amplify such a PKC-dependent activation of NAD(P)H oxidase. Additionally, human evidence showing the beneficial effect of antioxidants on diabetic vascular complications. Bilirubin has been recognized as a strong endogenous antioxidant. Here markedly lower prevalence of vascular complications is shown in diabetic patients with Gilbert syndrome, a congenital hyperbilirubinemia, as well as reduced markers of oxidative stress and inflammation. Lastly, statin, angiotensin II receptor blocker, chymase inhibitor, bilirubin and biliverdin, PKC β isoform inhibitor, and glucagon-like peptide-1 analog, are shown to serve as antioxidants and have some beneficial effect on diabetic vascular complications, via inhibiting PKC-NAD(P)H oxidase activation, supporting the notion that this mechanism may be an effective therapeutic target for preventing diabetic vascular complications.
氧化应激作为糖尿病血管并发症的一个重要致病因素受到越来越多的关注。在可能的各种来源中,越来越多的证据表明 NAD(P)H 氧化酶可能是糖尿病血管组织中活性氧产生的最重要来源。NAD(P)H 氧化酶的激活和上调的机制被认为是由高血糖诱导的蛋白激酶 C(PKC)激活介导的。在这篇综述文章中,还表明糜酶激活诱导的局部肾素-血管紧张素 II 系统的激活会放大这种 PKC 依赖性 NAD(P)H 氧化酶的激活。此外,还有人类证据表明抗氧化剂对糖尿病血管并发症的有益作用。胆红素已被认为是一种强大的内源性抗氧化剂。在这里,患有先天性高胆红素血症吉尔伯特综合征的糖尿病患者的血管并发症的明显较低的患病率,以及氧化应激和炎症标志物的降低,表明了这一点。最后,他汀类药物、血管紧张素 II 受体阻滞剂、糜酶抑制剂、胆红素和胆绿素、PKCβ 同工型抑制剂和胰高血糖素样肽-1 类似物,通过抑制 PKC-NAD(P)H 氧化酶的激活,被证明具有抗氧化作用,并对糖尿病血管并发症有一些有益的作用,这支持了这样一种观点,即这种机制可能是预防糖尿病血管并发症的有效治疗靶点。